Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

The $63,000 wholesale acquisition cost (WAC) for eight weeks of Harvoni™ (sofosbuvir and ledipasvir) should be extended to 12 and 24-week curative treatment durations.

Published
15 October 2014
From
Fair Pricing Coalition
If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Now that the FDA has approved the Harvoni treatment from Gilead Sciences and a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share. Already, though, some Wall Street prognosticators believe AbbVie may find it daunting.

Published
15 October 2014
From
Wall Street Journal
Care programme improves clinic attendance and rates of virologic suppression among vulnerable HIV-positive patients in New York

Enrolment in a comprehensive care co-ordination programme significantly improves levels of engagement with HIV care and virologic suppression in vulnerable HIV-positive adults, according to research published in the

Published
14 October 2014
By
Michael Carter
Nigel Farage defends plan to bar immigrants with HIV from NHS care

Farage, speaking during an LBC radio phone-in, was confronted by a Briton with HIV who accused him of “playing the race card” and that ramping up fear would make people with HIV hide rather than seek the treatment they needed.

Published
10 October 2014
From
The Guardian
As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

As Gilead Sciences launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions.

Published
10 October 2014
From
Forbes
BHIVA statement in response to the call by Nigel Farage to ban people with HIV from migrating to the UK

In response to today's comments by Nigel Farage in a Newsweek Europe interview, Dr David Asboe, Chair of the British HIV Association, said: "Mr Farage's suggestion that people with HIV should be banned from migrating to the UK is an example of the most deplorable kind of bigotry.

Published
10 October 2014
From
British HIV Association
Less Than Half of HIV-Positive US Hispanics Are Getting Proper Care

Even though Hispanics in the United States become infected with HIV at rates triple those of whites, less than half of Hispanics with the virus are receiving adequate treatment, a new report finds.

Published
10 October 2014
From
U.S. News & World Report
Thousands of Hep C patients in Alexandria wait in long lines to receive Sovaldi

Thousands of Hepatitis C virus patients have flooded two medical centers in Alexandria in hopes of receiving the new Hep C Sovaldi drug, after the health ministry said it will be providing it for patients.

Published
10 October 2014
From
Egypt Independent
HIV treatment roll-out has had only a modest impact on mortality in Lusaka, Zambia

The scale-up of antiretroviral therapy (ART) programmes in Lusaka, Zambia, has been accompanied by only modest reductions in the city’s mortality rates, investigators report in the Bulletin of the

Published
09 October 2014
By
Michael Carter
Sovaldi ‘unaffordable’ says NHS documents

Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after new data shows it would cost the health service £1 billion a year to fund.

Published
08 October 2014
From
Pharmafile

Filter by country